Rhythm Pharmaceuticals Inc has a consensus price target of $43.45, established from looking at the 45 latest analyst ratings. The last 3 analyst ratings were released from Needham, Goldman Sachs, and Needham on February 22, 2024, January 26, 2024, and January 26, 2024. With an average price target of $50.67 between Needham, Goldman Sachs, and Needham, there's an implied 15.15% upside for Rhythm Pharmaceuticals Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
02/22/2024 | RYTM | Buy Now | Rhythm Pharmaceuticals | $44.00 | 13.64% | Needham | Joseph Stringer | → $50 | Reiterates | Buy → Buy | Get Alert |
01/26/2024 | RYTM | Buy Now | Rhythm Pharmaceuticals | $44.00 | 18.18% | Goldman Sachs | Corinne Jenkins | $42 → $52 | Maintains | Buy | Get Alert |
01/26/2024 | RYTM | Buy Now | Rhythm Pharmaceuticals | $44.00 | 13.64% | Needham | Joseph Stringer | → $50 | Reiterates | Buy → Buy | Get Alert |
01/25/2024 | RYTM | Buy Now | Rhythm Pharmaceuticals | $44.00 | 18.18% | Goldman Sachs | Corinne Jenkins | $42 → $52 | Maintains | Buy | Get Alert |
01/04/2024 | RYTM | Buy Now | Rhythm Pharmaceuticals | $44.00 | 13.64% | Needham | Joseph Stringer | $45 → $50 | Maintains | Buy | Get Alert |
12/19/2023 | RYTM | Buy Now | Rhythm Pharmaceuticals | $44.00 | 25% | Morgan Stanley | Jeffrey Hung | $29 → $55 | Upgrade | Equal-Weight → Overweight | Get Alert |
12/19/2023 | RYTM | Buy Now | Rhythm Pharmaceuticals | $44.00 | 20.45% | Wells Fargo | Derek Archila | $48 → $53 | Maintains | Overweight | Get Alert |
12/07/2023 | RYTM | Buy Now | Rhythm Pharmaceuticals | $44.00 | -4.55% | Goldman Sachs | Corinne Jenkins | $38 → $42 | Maintains | Buy | Get Alert |
12/07/2023 | RYTM | Buy Now | Rhythm Pharmaceuticals | $44.00 | 2.27% | Needham | Joseph Stringer | $32 → $45 | Maintains | Buy | Get Alert |
11/08/2023 | RYTM | Buy Now | Rhythm Pharmaceuticals | $44.00 | -9.09% | Wells Fargo | Derek Archila | $38 → $40 | Maintains | Overweight | Get Alert |
10/10/2023 | RYTM | Buy Now | Rhythm Pharmaceuticals | $44.00 | -34.09% | Morgan Stanley | Jeffrey Hung | $28 → $29 | Maintains | Equal-Weight | Get Alert |
08/02/2023 | RYTM | Buy Now | Rhythm Pharmaceuticals | $44.00 | -36.36% | Morgan Stanley | Jeffrey Hung | $28 → $28 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
08/02/2023 | RYTM | Buy Now | Rhythm Pharmaceuticals | $44.00 | -38.64% | B of A Securities | Tazeen Ahmad | $22 → $27 | Upgrade | Neutral → Buy | Get Alert |
08/02/2023 | RYTM | Buy Now | Rhythm Pharmaceuticals | $44.00 | -27.27% | Needham | Joseph Stringer | → $32 | Reiterates | Buy → Buy | Get Alert |
06/20/2023 | RYTM | Buy Now | Rhythm Pharmaceuticals | $44.00 | -27.27% | Needham | Joseph Stringer | → $32 | Reiterates | Buy → Buy | Get Alert |
04/18/2023 | RYTM | Buy Now | Rhythm Pharmaceuticals | $44.00 | -27.27% | Needham | Joseph Stringer | → $32 | Reiterates | → Buy | Get Alert |
03/02/2023 | RYTM | Buy Now | Rhythm Pharmaceuticals | $44.00 | -36.36% | Morgan Stanley | Jeffrey Hung | $26 → $28 | Maintains | Equal-Weight | Get Alert |
03/02/2023 | RYTM | Buy Now | Rhythm Pharmaceuticals | $44.00 | 27.27% | Canaccord Genuity | Whitney Ijem | $52 → $56 | Maintains | Buy | Get Alert |
03/02/2023 | RYTM | Buy Now | Rhythm Pharmaceuticals | $44.00 | 2.27% | Goldman Sachs | Corinne Jenkins | $40 → $45 | Maintains | Buy | Get Alert |
The latest price target for Rhythm Pharmaceuticals (NASDAQ: RYTM) was reported by Needham on February 22, 2024. The analyst firm set a price target for $50.00 expecting RYTM to rise to within 12 months (a possible 13.64% upside). 16 analyst firms have reported ratings in the last year.
The latest analyst rating for Rhythm Pharmaceuticals (NASDAQ: RYTM) was provided by Needham, and Rhythm Pharmaceuticals reiterated their buy rating.
The last upgrade for Rhythm Pharmaceuticals Inc happened on December 19, 2023 when Morgan Stanley raised their price target to $55. Morgan Stanley previously had an equal-weight for Rhythm Pharmaceuticals Inc.
The last downgrade for Rhythm Pharmaceuticals Inc happened on November 19, 2021 when Morgan Stanley changed their price target from $50 to $15 for Rhythm Pharmaceuticals Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rhythm Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rhythm Pharmaceuticals was filed on February 22, 2024 so you should expect the next rating to be made available sometime around February 22, 2025.
While ratings are subjective and will change, the latest Rhythm Pharmaceuticals (RYTM) rating was a reiterated with a price target of $0.00 to $50.00. The current price Rhythm Pharmaceuticals (RYTM) is trading at is $44.00, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.